New Molecular Target for Cardiac Aging
心脏衰老的新分子靶点
基本信息
- 批准号:8985498
- 负责人:
- 金额:$ 31.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-15 至 2020-04-30
- 项目状态:已结题
- 来源:
- 关键词:ATP2A2AddressAdrenergic AgentsAdrenergic AgonistsAdrenergic AntagonistsAdrenergic ReceptorAffectAgeAgingAgonistAnimalsAttentionBiological AvailabilityBiological PreservationBlood VesselsCa(2+)-Transporting ATPaseCalciumCardiacCardiac MyocytesCardiac developmentCardiovascular PhysiologyCardiovascular systemCatecholaminesCell SizeCell physiologyChronicCongestive Heart FailureCouplingCyclic AMPCytochrome c Oxidase Subunit IVDiseaseDown-RegulationEffectivenessElderlyEquilibriumExerciseGelatinase BGene ExpressionGene TargetingGleanGrantHeartHomeostasisHumanIndiumInflammatoryIsoproterenolKnock-outKnowledgeLeadLeftMeasurementMeasuresMediatingMitochondrial ProteinsMolecularMolecular AnalysisMolecular TargetMorbidity - disease rateMusMuscle CellsMyocardialMyocardial dysfunctionNitratesNitric OxideNorepinephrineOutcomeOxidation-ReductionPathologicPathway interactionsPerformancePeroxonitritePhysiologicalPhysiologyPrevalencePreventionPropertyProtein IsoformsProteinsPublic HealthReceptor SignalingReceptor Up-RegulationRegulationResearch PersonnelRestReticulumRiskRoleRyanodine Receptor Calcium Release ChannelSignal PathwaySignal TransductionStressStructureSympathetic Nervous SystemSystemTestingTissuesUp-RegulationVentricularWild Type MouseWorkadrenergicage effectagedbeta-adrenergic receptorclinically significantcytochrome cdesensitizationelectric impedancehemodynamicshuman NOS2A proteininnovationinsightinterdisciplinary approachmitochondrial uncoupling protein 3mortalitynew therapeutic targetnitrationnoveloxidant stressphospholambanpressurepreventpublic health relevancereceptor densityreceptor expressionresponsesex
项目摘要
DESCRIPTION (provided by applicant): This application addresses one of the most fundamental aspects of the effect of aging on cardiovascular function, cardiac aging (CA), and congestive heart failure (CHF). Myocardial aging leads to a progressive decline in cardiac function and ß-adrenergic reserve, which increases the risk of CHF and cardiac morbidity. However, the precise mechanism is unclear. This grant investigates the role and mechanism of the signaling pathway mediated by ß3-adrenergic receptors (ARs) in CA. This pathway has negative effects on cardiac function, but has received limited attention in age-associated cardiac dysfunction. Our recent observations have shown that aging up-regulates cardiac ß3-ARs with enhanced ß3-AR-mediated negative modulations on cardiac function, [Ca2+]i regulation and the effectiveness of ß-adrenergic signaling. Chronic ß3-AR stimulation triggers up-regulation of cardiac inducible nitric oxide synthase (iNOS) and its uncoupling. Oxidant stress from iNOS uncoupling further aggravates cardiac dysfunction. These aging-induced alterations were prevented in ß3-AR knockout (ß3KO) aged mice and were reversed through treatment with a ß3-antagonist (ANT) in wild- type (WT) aged mice, suggesting that alteration of cardiac ß3-AR may be a critical element in the development of CA. We will test the Central Hypothesis that up-regulation of cardiac ß3-AR signaling, as a consequence of aging-induced sympathetic overdrive (with elevated catecholamine levels), not only contributes to, but is an important cause of CA. Thus, antagonizing ß3-AR with a selective ß3-ANT would be effective on the prevention and treatment of CA, leading to a normalization of ß3-AR expression and Ca2+ cycling/handling of cardiomyocytes, while contributing to the preservation of ß1-and ß2-ARs and ventricular arterial de-stiffening in the elderly. Studies will be conducted in age-matched and sex-matched SPF young and aged mice of control wild-type (WT), ß3KO, ß3TG/ß3KO and aged WT with and without chronic ß3-ANT treatment. Three specific aims are proposed to study intact animals, isolated cardiomyocytes, and molecular mechanisms. Using an integrative and multidisciplinary approach, serial and simultaneous measurements of LV structure alterations, LV and myocyte as well as vascular functional performance, cardiac calcium handling, gene expression, redox state, NOS coupling status, and neurohormonal activation in these animals will characterize the alterations of ß3-AR-mediated functional responses with related molecular and cellular signal transductions of CA and define the role and mechanism of ß3-ANT therapy in CA. This work will unravel aging-induced alterations at multiple levels (heart, cellular, sub-cellular, and molecular)
and glean crucial insights concerning how the balance of ß3- , ß1-, and ß2-ARs and the altered ß3-AR-mediated nitric oxide signaling affects cardiovascular performance in aging. This is a highly innovative proposal, and the outcomes will have a high impact, enhancing our understanding of the pivotal mechanisms of CA and CHF and may lead to new therapeutic targets for this important problem. These studies may also provide the rationale for the study of ß3-blockers in human CA.
描述(由申请人提供):本申请解决了衰老对心血管功能、心脏衰老(CA)和充血性心力衰竭(CHF)影响的最基本方面之一。 β-肾上腺素能储备,会增加CHF和心脏病的风险。然而,这项资助研究了β3-肾上腺素能介导的信号通路的作用和机制。该通路对心脏功能有负面影响,但在与年龄相关的心脏功能障碍中受到的关注有限。我们最近的观察表明,衰老会上调心脏 ß3-AR,并增强 ß3-AR 介导的负作用。对心脏功能的调节、[Ca2+]i 调节和 ß-肾上腺素信号传导的有效性会触发心脏诱导型一氧化氮合酶的上调。 (iNOS) 及其解偶联导致的氧化应激进一步加剧了 ß3-AR 敲除 (ß3KO) 老年小鼠的心脏功能障碍,并通过在野生小鼠中使用 ß3 拮抗剂 (ANT) 进行治疗来逆转。型 (WT) 老年小鼠,表明心脏 ß3-AR 的改变可能是 CA 发展的关键因素,我们将检验中心假设。由于衰老引起的交感神经过度兴奋(儿茶酚胺水平升高),心脏 ß3-AR 信号传导上调不仅会导致 CA,而且是 CA 的一个重要原因,因此,用选择性 ß3 拮抗 ß3-AR。 -ANT 可有效预防和治疗 CA,导致 ß3-AR 表达和心肌细胞 Ca2+ 循环/处理正常化,同时有助于保存将在年龄匹配和性别匹配的 SPF 年轻和老年小鼠中进行对照野生型 (WT)、ß3KO、ß3TG/ß3KO 和老年 WT 的 ß1-和 ß2-AR 以及心室动脉去硬化研究。提出了三个具体目标来研究完整的动物、分离的心肌细胞和分子机制。对这些动物的 LV 结构改变、LV 和肌细胞以及血管功能性能、心脏钙处理、基因表达、氧化还原状态、NOS 偶联状态和神经激素激活的连续和同时测量将表征 ß3-AR- 的变化介导与 CA 相关分子和细胞信号转导的功能反应,并定义 ß3-ANT 治疗在 CA 中的作用和机制。这项工作将揭示衰老引起的多个水平(心脏、细胞、亚细胞、分子)
并收集关于 ß3-、ß1- 和 ß2-AR 的平衡以及 ß3-AR 介导的一氧化氮信号传导的改变如何影响衰老过程中心血管功能的重要见解。这些研究也可能为人类 CA 中 ß3 阻滞剂的研究提供理论基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Heng-Jie Cheng其他文献
Heng-Jie Cheng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Heng-Jie Cheng', 18)}}的其他基金
相似国自然基金
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
Community-informed approaches to the escalating presence of xylazine in opioids
针对阿片类药物中甲苯噻嗪含量不断增加的社区知情方法
- 批准号:
10701304 - 财政年份:2023
- 资助金额:
$ 31.78万 - 项目类别:
Autonomic Dysfunction in Patients with HFpEF
HFpEF 患者的自主神经功能障碍
- 批准号:
10587484 - 财政年份:2023
- 资助金额:
$ 31.78万 - 项目类别:
Evaluating the role of hypoleptinemia in impaired counterregulatory responses to hypoglycemia
评估低瘦素血症在低血糖反调节反应受损中的作用
- 批准号:
10586777 - 财政年份:2023
- 资助金额:
$ 31.78万 - 项目类别:
The role of S-glutathione in regulating cardiac myosin binding protein-C function
S-谷胱甘肽在调节心肌肌球蛋白结合蛋白-C功能中的作用
- 批准号:
10749281 - 财政年份:2023
- 资助金额:
$ 31.78万 - 项目类别:
Structural Racism, Pharmacy Closures and Disparities in Medication Adherence Among Older Adult Medicare Part-D Beneficiaries
结构性种族主义、药房关闭以及老年人医疗保险 D 部分受益人的药物依从性差异
- 批准号:
10568717 - 财政年份:2023
- 资助金额:
$ 31.78万 - 项目类别: